GSK plc (GSK)
GSK trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1131399/000113139926000004/0001131399-26-000004-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31. Converted from GBP at 0.7538 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | GSK on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | 2022 |
| SEC CIK | 0001131399 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | X0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $43.3B |
| Net income | $7.6B |
| Operating income | Not in SEC XBRL data |
| Net margin | 17.5% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 12.3× |
| P/S (computed) | 2.2× |
Reported in GBP; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-09-10 |
| Latest annual report | 20-F | 2026-03-06 |
| Latest quarterly / interim DIRECTOR/PDMR SHAREHOLDING | 6-K | 2026-10-14 |
Source: SEC EDGAR submissions feed, 1,005 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.8% |
| 1 month | -4.3% |
| 3 months | -9.3% |
| Year to date | -2.4% |
| 1 year | +9.6% |
| From 52-week high | -21.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SNY | Sanofi ADS | $39.12 | -1.56% | $95.4B |
| REGN | Regeneron Pharmaceuticals Inc. | $753.12 | -1.27% | $77.5B |
| BMY | Bristol-Myers Squibb Company | $56.67 | -1.58% | $115.8B |
| VRTX | Vertex Pharmaceuticals Incorporated | $485.22 | -4.30% | $123.0B |
| TAK | Takeda Pharmaceutical Company Limited | $18.52 | -0.86% | $58.5B |
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
| NVO | Novo Nordisk A/S | $38.06 | -1.35% | $168.5B |
| ABT | Abbott Laboratories | $102.61 | +0.78% | $177.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier